M
Mammogen
Dedicated to meaningfully improving every aspect of women's health
About Mammogen
Mammogen is a biotechnology startup led by women, aiming to revolutionize the detection, diagnosis, and treatment of women's health-related diseases. The company leverages data, technology, and science to challenge the status quo and improve women's health outcomes. Mammogen's mission is not just about survival, but also about empowering women to thrive and take control of their health.
Read full description
The company operates in the biotech market, specifically focusing on women's health. It serves a broad range of clients, including healthcare providers and women seeking better healthcare solutions. Mammogen's business model revolves around creating innovative solutions for early detection and easier diagnosis of women's diseases, thereby improving treatment options.
Mammogen aims to create a global community for women, providing not just end-to-end care, but an 'end-to-never-end' support system. The company is committed to addressing not just physical health issues, but also the emotional and psychological challenges that women face, such as fear, anxiety, depression, marital challenges, and body-shame issues.
The company generates revenue by providing these innovative healthcare solutions to its clients. By focusing on early detection, easier diagnosis, and better treatment, Mammogen aims to reduce the overall cost of women's healthcare, while improving the quality of care and support provided.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Aliso Viejo, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 83.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Mammogen.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2026 | $30M | $120M | Undisclosed | ↗ |
| SEED✓Equity / VC | Jun 2021 | $2M | $8M | Undisclosed | — |
Growth signals
Latest recorded traffic for Mammogen is 460 monthly website visits, up 24.3% over the last three months. Mammogen's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mammogen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mammogen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.